Core Insights - Zimmer Biomet Holdings, Inc. (ZBH) is a leading global medical technology company specializing in musculoskeletal healthcare solutions, with a market cap of approximately $18.7 billion [1][2] Company Overview - ZBH focuses on orthopedic reconstructive implants, sports medicine products, biologics, dental implants, and robotic-assisted surgical technologies [1] - The company has a history dating back to 1927 and is recognized as a major player in the orthopedic device industry [2] Stock Performance - Zimmer Biomet stock has decreased by 17.9% from its 52-week high of $114.44 reached in April 2025, but has gained 3.3% over the past three months, outperforming the iShares U.S. Medical Devices ETF (IHI), which declined by 10.8% during the same period [3] - Year-to-date, ZBH has increased by 4.5%, while it has experienced a 14.6% decline over the past 52 weeks, compared to IHI's decline of 10.7% in 2026 and 6.2% over the past year [3] Technical Analysis - The stock is currently trading below the 200-day moving average but remains above the 50-day moving average this month [4] Financial Performance - In 2025, ZBH reported full-year revenue of $8.2 billion, reflecting a year-over-year increase of 7.2% [5] - Adjusted EPS rose to $8.20 in 2025 from $8.00 in 2024, exceeding expectations [5] Strategic Initiatives - The company has announced a $1.5 billion share repurchase program, indicating confidence in future cash flows [6] - There is growing excitement around ZBH's robotic-assisted surgery systems and smart implant technologies, which are expected to support long-term growth [6] Competitive Position - Despite its strengths, Zimmer Biomet has underperformed compared to its peer Medtronic plc (MDT), which saw an 8.6% decline year-to-date and a 5.7% dip over the past year [6]

Company Overview - Zimmer Biomet Holdings, Inc. (ZBH) has a market capitalization of $19.6 billion and specializes in musculoskeletal healthcare solutions, including orthopedic reconstructive implants and various medical technologies [1] - The company is classified as a "large-cap" stock, which typically includes companies valued over $10 billion [2] Stock Performance - ZBH shares have decreased by 13.6% from their 52-week high of $114.72, while returning 7.6% over the past three months, in line with the Dow Jones Industrials Average [3] - Year-to-date, ZBH stock has declined by 6.2%, underperforming the Dow Jones Industrials Average, which has increased by 7.6% [4] - Over the past 52 weeks, ZBH shares have dropped 7.7%, compared to a 9.9% rise in the Dow Jones Industrials Average [4] - Despite recent declines, ZBH stock has been trading above its 50-day moving average since early August [5] Recent Financial Results - On August 7, ZBH shares rose nearly 8% following the release of better-than-expected Q2 2025 results, reporting adjusted EPS of $2.07 and revenue of $2.08 billion [6] - The company raised its 2025 adjusted EPS forecast to between $8.10 and $8.30, exceeding analyst expectations, and reduced anticipated tariff headwinds to approximately $40 million [6] Competitive Landscape - ZBH has underperformed compared to its rival, Penumbra, Inc. (PEN), which has seen a YTD increase of 10.7% and a 52-week increase of 40.1% [7] - Analysts maintain a moderately optimistic outlook for ZBH, with a consensus rating of "Moderate Buy" from 27 analysts and a mean price target of $110.96, indicating an 11.9% premium to current levels [7]